Financial Performance - Total revenue for Q1 2025 was $15.8 million, representing a 31% year-over-year increase[5] - Software revenue reached $5.2 million, a 2% year-over-year increase[5] - Operating expenses decreased by $1.8 million, a 9% year-over-year improvement[5] - Net loss for Q1 2025 was $(11.3) million, an 18% year-over-year improvement[5] - Adjusted EBITDA for Q1 2025 was $(7.4) million, a 22% year-over-year decrease[5] Liquid Assets and Cash Flow - As of December 31, 2025, total liquid assets were approximately $34.7 million, a decrease of $40.7 million from December 31, 2024[7] - The decrease in liquid assets was partly due to $18.9 million in outflows related to legal fees and settlements[7] - The company anticipates that total cash outflows from operating and non-recurring activities will be significantly lower in 2026 compared to 2025[7] Strategic Focus and Risks - The company is focused on completing its SEC filings and advancing the DOOR platform to enhance long-term value for stakeholders[4] - The company continues to operate under the legal name Latch, Inc., with shares trading under the symbol "LTCH" until a corporate name update is made[15] - The Company emphasizes the importance of implementing its business plans to achieve revenue forecasts[27] - There are potential risks including unexpected delays and expenditures that could impact future performance[27] - The Company does not guarantee that it will meet its expectations as outlined in forward-looking statements[27]

Delaware 001-37824 91-2041398 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 13, 2026 Impinj, Inc. (Exact name of registrant as specified in its charter) 400 Fairview Avenue North, Suite 1200 Seattle, Washington 98109 (Address o ...

Financial Results - Rapid Micro Biosystems, Inc. announced preliminary unaudited revenue results for Q4 2025 and the full year ended December 31, 2025[3]. - The press release detailing the financial results was issued on January 13, 2026[3]. - The financial statements and exhibits related to the report are not deemed "filed" under the Securities Exchange Act of 1934[4]. Company Classification - The company is classified as an emerging growth company under the Securities Act of 1933[3]. Reporting Format - The report includes a cover page interactive data file formatted as inline XBRL[6]. Management - Sean Wirtjes serves as the Chief Financial Officer of Rapid Micro Biosystems, Inc.[10].

Financial Performance - Revenue for Q4 FY 2025 was $108.8 million, a decrease of 2.4% from $111.5 million in Q4 FY 2024[5] - Gross profit for Q4 FY 2025 was $43.3 million, down from $46.2 million, with a gross margin decline of 170 basis points to 39.8%[7] - Net income for Q4 FY 2025 was $5.3 million, compared to $9.4 million in the prior year quarter, resulting in diluted earnings per share of $0.09 versus $0.16[8] - Adjusted EBITDA for Q4 FY 2025 was $30.7 million, down from $33.7 million, with an adjusted EBITDA margin of 28.2% compared to 30.2%[9] - For FY 2025, revenue was $392.9 million, a decrease of 7.8% from $425.9 million in FY 2024[10] - Net income for FY 2025 was $6.4 million, down from $16.2 million in FY 2024, with diluted earnings per share of $0.09 compared to $0.26[12] - Revenue for the three months ended October 31, 2025, was $108.8 million, a decrease of 2.3% from $111.5 million in the same period of 2024[38] - Net income for the year ended October 31, 2025, was $6.4 million, compared to $16.2 million in 2024, reflecting a decline of 60.5%[39] - Total revenue for the three months ended October 31, 2025, was $108,787, a decrease of $2,696 or 2.4% compared to $111,483 in the same period of 2024[40] - Consolidated net income for the three months ended October 31, 2025, was $5,317, compared to $9,427 for the same period in 2024, representing a decrease of 43.5%[48] Liquidity and Capital Expenditures - Total available liquidity at the end of Q4 FY 2025 was $359.5 million, down from $378.0 million a year ago[5] - The company plans to accelerate approximately $22.0 million of capital equipment investments into FY 2026 due to upcoming stricter emissions laws[21] - Capital expenditures for Q1 2025 included approximately $2 million for growth investments[46] - Capital expenditures for Q2 2025 included approximately $2 million for growth investments[47] Segment Performance - U.S. Concrete Waste Management Services revenue increased 8% in Q4 FY 2025 to $21.3 million, driven by organic volume growth and pricing improvements[16] - U.S. Concrete Pumping segment revenue decreased by $2,343 or 3.1% to $72,161 for the three months ended October 31, 2025, compared to $74,504 in 2024[40] - U.S. Concrete Waste Management Services segment revenue increased by $1,492 or 7.5% to $21,329 for the three months ended October 31, 2025, compared to $19,837 in 2024[40] - U.K. Operations segment revenue decreased by $1,845 or 10.8% to $15,297 for the three months ended October 31, 2025, compared to $17,142 in 2024[40] - U.S. Concrete Waste Management Services segment net income increased by $393 or 7.2% to $5,853 for the year ended October 31, 2025, compared to $5,460 in 2024[44] - U.S. Concrete Pumping segment reported a net income of $1,131 for the three months ended October 31, 2025, compared to $3,778 in 2024, a decrease of 70.0%[48] - U.S. Concrete Waste Management Services segment achieved a net income of $3,037 for the three months ended October 31, 2025, slightly down from $3,932 in 2024, a decrease of 22.8%[49] - U.K. Operations reported a net income of $1,154 for the three months ended October 31, 2025, compared to $1,720 in 2024, a decrease of 32.9%[49] Debt and Interest - Total net debt as of October 31, 2025, was $380,606, a decrease from $387,212 as of April 30, 2025[50] - The company incurred interest expense of $8,200 for the three months ended October 31, 2025, compared to $5,976 in the same period of 2024, an increase of 37.0%[48] - Net debt as of October 31, 2025, was calculated as total debt obligations less cash, providing insight into the company's leverage[31] - The leverage ratio, defined as net debt to Adjusted EBITDA, is a standard measurement used by investors to assess creditworthiness[32] Other Financial Metrics - Adjusted EBITDA for the year ended October 31, 2025, was not explicitly stated but is a key measure for evaluating ongoing operating results[30] - Free cash flow for the year ended October 31, 2025, is defined as Adjusted EBITDA less net maintenance capital expenditures and cash paid for interest[33] - Total current assets increased slightly to $113.4 million as of October 31, 2025, compared to $112.4 million in 2024[37] - Total liabilities increased to $589.8 million as of October 31, 2025, from $551.3 million in 2024[37] - The company reported a decrease in accumulated deficit to $(85.0) million as of October 31, 2025, compared to $(38.2) million in 2024[37] - Depreciation and amortization for the year ended October 31, 2025, was $53,543, down from $57,110 in 2024, a decrease of 6.5%[48] - The company reported a loss on debt extinguishment of $1,392 for the year ended October 31, 2025[48] - Other adjustments for the year ended October 31, 2025, included a non-recurring charge related to sales tax litigation amounting to $3.5 million[51]

Financial Outlook - As of December 31, 2025, Precision BioSciences expects to report approximately $137 million in cash, cash equivalents, and restricted cash[8] - The company anticipates that its cash runway will extend through 2028, supported by existing cash, potential near-term licensee considerations, and fiscal discipline[9] Clinical Trials - Additional biopsy data from the ELIMINATE-B trial for PBGENE-HBV is expected in the first half of 2026[12] - The FUNCTION-DMD Phase 1/2 clinical trial in Duchenne muscular dystrophy patients is expected to dose the first patient in late Q1 or early Q2 2026, with initial data anticipated by year-end 2026[13] Strategic Priorities - The company has set strategic priorities for 2026, as announced in a press release on January 12, 2026[10]

Financial Performance - Cytek Biosciences, Inc. announced preliminary unaudited revenue for Q4 and full year 2025 on January 12, 2026[4] - The report does not include specific financial figures or performance metrics in the provided content[4] Company Information - The company is listed on the Nasdaq Global Select Market under the symbol CTKB[2]

Financial Performance - Software revenue for Q1 2025 was $5,159,000, a 2.4% increase from $5,037,000 in Q1 2024[149] - Total revenue for Q1 2025 reached $15,774,000, representing a 31.1% increase from $12,035,000 in Q1 2024[149] - Net loss for Q1 2025 was $11,250,000, a reduction of 17.5% compared to a net loss of $13,637,000 in Q1 2024[149] - Adjusted EBITDA for Q1 2025 was $(7,384,000), compared to $(6,077,000) in Q1 2024, reflecting a 21.5% increase in losses[149] - Total revenue for the three months ended March 31, 2025, increased by $3.7 million, or 31.1%, compared to the same period in 2024, driven primarily by a $4.2 million increase in professional services revenue[172] - The net loss for the three months ended March 31, 2025, was $11.3 million, a decrease of $2.4 million, or 17.5%, compared to the same period in 2024[172] Revenue Breakdown - Hardware revenue is generated from the sale of smart access and smart home devices, recognized upon transfer of control to customers[154] - Professional services revenue includes project-based hardware installation, technology services through HelloTech, and property management services[157] - Professional services revenue rose by 179.3% to $6.6 million for the three months ended March 31, 2025, largely due to the acquisition of HelloTech[173] Costs and Expenses - Total cost of revenue increased by $2.7 million, or 48.6%, for the three months ended March 31, 2025, primarily due to a $2.2 million rise in professional services costs[175] - Research and development expenses increased by $1.4 million, or 34.1%, for the three months ended March 31, 2025, mainly due to a rise in third-party expenses[176] - General and administrative expenses decreased by $3.9 million, or 33.1%, for the three months ended March 31, 2025, due to reductions in various non-ordinary course expenses[178] Cash Flow and Liquidity - As of March 31, 2025, the company's unrestricted cash and cash equivalents were approximately $64.7 million[182] - The company had approximately $33.5 million in net inventory as of March 31, 2025[183] - Net cash used in operating activities for Q1 2025 was $(10,137) thousand, a decrease of $21.0 million compared to $(31,100) thousand in Q1 2024[197] - Net cash used in investing activities was $(935) thousand in Q1 2025, a significant decrease of $46.1 million from net cash provided of $45,162 thousand in Q1 2024[198] - Net cash used in financing activities was $(223) thousand in Q1 2025, with no financing activities reported in Q1 2024[199] - The company experienced a $20.6 million reduction in cash outflows related to litigation and restructuring activities in Q1 2025[197] - Management is focusing on cost discipline, inventory management, and liquidity preservation to reduce operating cash usage[197] - The company expects to use its current cash and cash equivalents and available-for-sale securities to fund operational cash requirements for at least 12 months from the date of the report[189] Legal and Regulatory Matters - The company is involved in ongoing litigation and legal disputes, with non-ordinary course legal fees impacting financial results[156] - There were no off-balance sheet arrangements as of March 31, 2025, that could materially affect the company's financial condition[201] - No material changes were reported in critical accounting estimates since the 2024 Annual Report[202] - The company did not incur any significant market risk disclosures as it qualifies as a smaller reporting company[204] Leadership Changes - The company has appointed new executive leadership, including David Lillis as CEO and Jeff Mayfield as CFO, effective February 6, 2025[147] Supply Chain and Cost Expectations - The company expects hardware costs to align with revenue, influenced by supply chain constraints and shipping cost volatility[161]

Financial Performance - Total revenue for Q3 fiscal 2026 was $7.5 million, down from $7.9 million in the year-ago quarter, reflecting the company's exit from lower-margin channels [5]. - Gross profit increased to $1.4 million in Q3 fiscal 2026 compared to $0.7 million in the year-ago quarter, driven by pricing actions and improved product mix [5]. - Net loss narrowed to $0.2 million or $(0.02) per share in Q3 fiscal 2026, compared to a net loss of $0.8 million or $(0.11) per share in the year-ago quarter [5]. - EBITDA improved to $0.4 million in Q3 fiscal 2026 from a loss of $(0.4) million in the year-ago quarter, attributed to increased gross profit and lower costs [5]. - For the three months ended November 30, FY26, the net loss was $155,000, a decrease from a net loss of $847,000 in FY25 [16]. - EBITDA for FY26 was $427,000, a significant improvement compared to an EBITDA of $(420,000) in FY25 [16]. - Depreciation and amortization increased to $345,000 in FY26 from $274,000 in FY25 [16]. - Interest expenses rose to $237,000 in FY26, up from $153,000 in FY25 [16]. Strategic Initiatives - The company executed a franchise area development agreement to bring 34 new stores to market, indicating strong franchise development momentum [3]. - A $2.7 million equity capital raise was completed to reduce leverage and enhance liquidity for strategic investments [3]. - Over 120 franchise stores are now utilizing the new point-of-sale platform, improving visibility into customer behavior and store performance [4]. - The company is focusing on a margin-first strategy, prioritizing profitability through pricing adjustments and SKU rationalization [2]. Operational Efficiency - Total costs and expenses decreased to $7.5 million in Q3 fiscal 2026 from $8.6 million in the year-ago quarter, with savings across operations [5]. - The company operates over 250 stores across the U.S. and has been recognized in Entrepreneur's Franchise 500® for 2025 [8].

Exhibit 99.1 News Release Phoenix Education Partners, Inc. Reports First Quarter Fiscal Year 2026 Results Phoenix, January 13, 2026 – Phoenix Education Partners, Inc. (NYSE: PXED) (the "Company" or "Phoenix Education Partners"), the parent company of The University of Phoenix, Inc. (the "University"), today reported financial results for the three months ended November 30, 2025, with first quarter revenue of $262.0 million. "Guided by our mission to serve working adults through skills-aligned, career-releva ...

Financial Projections - 2025 projected topline growth of 30% and a 10-year revenue CAGR of 20%[4] - Net sales for 2023 were $283 million, with a projected increase to $383 million in 2024 and $610 million in 2026, reflecting a 20%+ 10-year CAGR[25] - Preliminary unaudited net sales for FY2025 were $507 million as of January 13, 2026[25] - Revenue guidance for FY2026 is set at $610 million, indicating strong growth expectations[25] Research and Development - $800 million invested in R&D since 2018, supporting a robust pipeline of 12 programs[4] - iDose platform expansion includes 6+ future products designed to enhance utilization and applicability[9] - The company is currently in Phase 2 clinical trials for its customized spherical therapy for keratoconus, which aims to enhance patient experience and treatment efficacy[20] - The Retina XR platform targets a market of over 28 million people in the US affected by retinal diseases, with an estimated market size exceeding $10 billion by 2024[23] Product Innovations - iDose TR designed to deliver up to 3 years of drug therapy, with 81% of subjects free of IOP-lowering topical meds at 12 months[8] - New Phase 3 data analysis shows iDose TR is non-inferior to topical timolol at 3 years[9] - iStent infinite launched in 2025, providing up to 240° of outflow coverage, backed by 14 years of commercial MIGS leadership[10] - The product roadmap includes several FDA-approved products such as iDose TR for ocular hypertension and Epioxa for keratoconus, with Epioxa expected to launch in Q1 2026[13][21] - The iDose TR product received FDA approval in 2023, further strengthening the company's portfolio in glaucoma treatment[24] Market Opportunities - The company reported a patient population of 22 million eyes with 13 million diagnosed and 12 million treated for glaucoma, indicating a significant market opportunity[11] - Annual US cataract procedures are estimated at 15 million eyes, with a projected professional fee reduction of approximately 15-20% for procedures involving co-morbid glaucoma[12] - The estimated US market size for demodex blepharitis is projected to reach $400 million by 2025, indicating a substantial growth opportunity for the iLution platform[22] Company Positioning and Strategy - Glaukos aims to fundamentally reset keratoconus management, improving patient access to effective care[5] - The company is positioned to lead the shift towards a proactive, compliance-independent glaucoma care paradigm[7] - The company is focusing on expanding its market access and patient education initiatives to improve awareness and treatment rates for keratoconus and other rare diseases[18] - The company emphasizes innovation in addressing unmet needs in chronic eye diseases, positioning itself as a leader in the industry[26] Financial Health - Gross margin for Q3 2025 was reported at 84%, adjusted for certain accounting and other adjustments[27] - The gross profit for Q3 2025 was $112 million, with a gross margin of 78% on a GAAP basis[27] - Cash and equivalents stood at $283 million as of December 31, 2025, with no debt reported[25] Operational Capabilities - The company operates in 17 countries with over 300 global commercial personnel, indicating significant market presence[25] - The sales mix for Q4 2025 includes US Glaucoma, Corneal Health, and International Glaucoma segments[25] - The company is enhancing its manufacturing capabilities with a new facility in Huntsville, AL, to support its micro-scale manufacturing expertise[25] Patient Compliance and Preferences - 90% of patients are non-compliant with topical eye drops, highlighting the need for innovative solutions[6] - Strong user preference (~90% favorability) indicated in initial human factors study for new iDose products[9] - The company is pursuing dropless innovations to enhance care standards and improve outcomes for underserved patient populations[24]